The reimbursement difficulties faced in the UK by the CAR-T therapies Kymriah and Yescarta could be illustrative of the hurdles they will have to leap in other EU countries, which will have similar concerns over cost and the lack of comparator studies that have caused the health technology assessment (HTA) body NICE to issue preliminary guidance rejecting their routine use on the National Health Service.
On the other hand, HTA bodies in Europe are clearly impressed by the products, and if cost-effectiveness can be demonstrated effectively, payers are likely to look favorably on
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?